公开(公告)号：US11434201B2

公开(公告)日：2022-09-06

申请号：US16635346

申请日：2018-08-02

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul T. Angell ,  Robert M. Hughes ,  Berenice Lewandowski ,  Benjamin J. Littler ,  William A. Nugent ,  David Smith ,  John Studley

IPC: C07D207/06

Abstract: Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are disclosed.

公开(公告)号：US20200369608A1

公开(公告)日：2020-11-26

申请号：US16635346

申请日：2018-08-02

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul T. Angell ,  Robert M. Hughes ,  Berenice Lewandowski ,  Benjamin J. Littler ,  William A. Nugent ,  David Smith ,  John Studley

IPC: C07D207/06

Abstract: Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are disclosed.

公开(公告)号：US20240025877A1

公开(公告)日：2024-01-25

申请号：US17899672

申请日：2022-08-31

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul T. Angell ,  Cristian Harrison ,  Robert M. Hughes ,  Berenice Lewandowski ,  Benjamin J. Littler ,  Vito Melillo ,  William A. Nugent ,  David Andrew Siesel ,  David Smith ,  John Studley

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The disclosure provides processes for preparing a compound of Formula (I):

公开(公告)号：US11465985B2

公开(公告)日：2022-10-11

申请号：US16769047

申请日：2018-12-07

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul T. Angell ,  Cristian Harrison ,  Robert M. Hughes ,  Berenice Lewandowski ,  Benjamin J. Littler ,  Vito Melillo ,  William A. Nugent ,  David Andrew Siesel ,  David Smith ,  John Studley

IPC: C07D401/14

Abstract: The disclosure provides processes for preparing a compound of Formula (I).

公开(公告)号：US20210246117A1

公开(公告)日：2021-08-12

申请号：US16769047

申请日：2018-12-07

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul T. Angell ,  Cristian Harrison ,  Robert M. Hughes ,  Berenice Lewandowski ,  Benjamin J. Littler ,  Vito Melillo ,  William A. Nugent ,  David Andrew Siesel ,  David Smith ,  John Studley

IPC: C07D401/14

Abstract: The disclosure provides processes for preparing a compound of Formula (I).

公开(公告)号：US10231932B2

公开(公告)日：2019-03-19

申请号：US15035969

申请日：2014-10-31

Applicant: VERTEX PHARMACEUTICALS INCORPORATED

Inventor： Kelly Ann Swinney ,  Patricia Nell Hurter ,  David E. Nadig ,  David Smith ,  Vance Hayden Thomas ,  Martin Paul Warman

IPC: A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/47 ,  A61K45/06 ,  A61K31/443

Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.